IBRXImmunityBioIBRX info
$3.42info3.01%24h
Global rank4750
Market cap$2.29B
Change 7d-19.91%
YTD Performance-31.46%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    ImmunityBio (IBRX) Stock Overview

    ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, toll-Like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company is based in San Diego, California.

    IBRX Stock Information

    Symbol
    IBRX
    Address
    3530 John Hopkins CourtSan Diego, CA 92121United States
    Founded
    -
    Trading hours
    9:30 AM - 4:00 PM ET
    Website
    https://immunitybio.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    858 633 0300

    ImmunityBio (IBRX) Price Chart

    -
    Value:-

    ImmunityBio Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $3.42
    N/A
    Market Cap
    $2.29B
    N/A
    Shares Outstanding
    670.33M
    N/A
    Employees
    670.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org